Regeneron Pharmaceuticals: An Insight Into EYLEA Revenue and Market Dynamics! 

Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while facing challenges in others. Overall, the company reported total revenues of $3.7 billion, marking a year-over-year increase of 4%, primarily buoyed by the impressive sales growth of flagship therapies like Dupixent and Libtayo, as well as the introduction and expansion of EYLEA HD. However, the legacy EYLEA product witnessed a significant decline, with U.S. sales dropping 39% from the previous year due to competitive pressures and ongoing shifts toward EYLEA HD.